Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
SALT LAKE CITY, Sept. 20, 2016 -- Sera Prognostics, Inc., a women’s healthcare company, today announced that Gregory C. Critchfield, M.D., M.S., Chairman and Chief Executive Officer, will present at the upcoming Ladenburg Thalmann 2016 Healthcare Conference. Dr. Critchfield’s presentation will take place at 11:00 AM ET on Tuesday, September 27th, at the Sofitel Hotel in New York.
Sera Prognostics management will be available for one-on-one meetings with conference attendees during the day. To schedule a meeting with management, please contact Andrew Sauter, Chief Financial Officer at [email protected].
About Sera Prognostics, Inc.
Sera Prognostics, a women’s health company, develops innovative diagnostic tests focused on the early prediction of preterm birth (PTB) risk and other complications of pregnancy. Sera has launched its PreTRM® test, the first and only clinically validated blood test to accurately predict early in pregnancy the risk of premature birth. The test objectively reports to the physician the risk of premature delivery, enabling earlier proactive interventions designed to prolong gestation and improve neonatal health outcomes. Sera’s proprietary technology addresses both the health and economic challenges of PTB. Its strong management team has significant clinical development and women's healthcare diagnostic experience. Sera is backed by highly respected healthcare investors, including Domain Associates, InterWest Partners, Catalyst Health Ventures, and the Bill & Melinda Gates Foundation. Currently, Sera is working with the Gates Foundation to translate the Company’s discoveries into alternative technologies ideal for low-income countries in its journey to improve maternal and infant health globally. Sera Prognostics is located in Salt Lake City, Utah. For more information, please visit the company's website at www.seraprognostics.com.
Company Contact: Andrew Sauter Sera Prognostics [email protected] (801) 990-0772 Communications Contact Terri Clevenger Continuum Health Communications [email protected] (203)856-4326
